Sun Nuclear Corp

Sun Nuclear Corp's Medical Division, doing business as Cirs, manufactures medical imaging and radiation therapy simulation phantoms for the federal government as a 100% prime contractor, with no set-aside designations across its award footprint. Headquartered in Norfolk, Virginia, the company is a for-profit manufacturer classified primarily under NAICS 334517 (Surgical and Medical Instrument Manufacturing) and operates competitively on full-and-open procurements without SBA certifications.

Cirs delivers tissue-simulation phantoms and specialized medical imaging equipment used in diagnostic training, research validation, and quality assurance across healthcare and oncology settings. Representative prime work includes a $256,500 firm fixed-price purchase order from the Department of Veterans Affairs, Veterans Integrated Service Network 10, awarded February 2, 2026, for medical imaging and radiation therapy simulation phantoms at the Cleveland VAMC, running through January 31, 2031 with four one-year option periods; a $397,148 National Institutes of Health Small Business Innovation Research Phase I award from the National Cancer Institute, dated September 16, 2021, for multi-compartment phantom materials for quantitative multi-parametric MRI of the prostate; and an $84,455 purchase order from the Defense Health Agency, dated September 17, 2024, for ARCCHECK 4D Isotropic Arc oncology detector phantoms. Additional recent awards span PHANTOM LUNG ($68,061, VA VISN 19, September 2023), Dynamic Thorax Phantom ($50,864, VA VISN 20, August 2024), CIRS Body Composition Phantom equipment ($112,420, VA VISN 1, January 2022), and XSIGHT Lung Tracking Phantom ($41,929, VA VISN 1, March 2022).

Customer concentration centers on healthcare and medical research agencies. The top five funding agencies account for 56% of awards by count and 72% by combined potential value, led by the National Institutes of Health National Cancer Institute (5 awards, $440 thousand), the Department of Veterans Affairs Veterans Integrated Service Network 10 ($257 thousand from a single recent award), VA VISN 1 (2 awards, $154 thousand), the Food and Drug Administration (12 awards, $131 thousand), and VA VISN 19 (3 awards, $94 thousand). Across the full 48-award portfolio, the company has served 17 distinct customer agencies spanning the Veterans Health Administration, National Institutes of Health, National Cancer Institute, Food and Drug Administration, Defense Health Agency, and Department of the Navy Bureau of Medicine and Surgery.

Award activity has been sparse and irregular — two awards in 2021 and 2022, one in 2023, two in 2024, and one year-to-date in 2026 — reflecting small, episodic purchase orders rather than sustained contract vehicles or recurring task-order relationships. Combined potential value across all 48 awards is $1.5 million, with $1.3 million obligated (86% of potential value), indicating mature execution across the footprint. Cirs does not occupy any named parent contract vehicles, GWACs, or BPAs; every award is a standalone purchase order or grant. The company has no documented subcontractor presence and does not appear in prime contractor supply chains.